Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 23, 2016

Galapagos begins DIVERSITY Phase III study of filgotinib to treat Crohn’s disease

Belgium-based clinical-stage biotechnology company Galapagos has begun its DIVERSITY Phase III study of filgotinib to treat Crohn’s disease (CD).

Belgium-based clinical-stage biotechnology company Galapagos has begun its DIVERSITY Phase III study of filgotinib to treat Crohn’s disease (CD).

Filgotinib is a highly selective, Janus kinase 1 (JAK1) inhibitor discovered and developed by Galapagos using its target and drug discovery technology platform.

Crohn's disease is an inflammatory bowel disease (IBD) that causes the inflammation of the lining of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition.

The inflammation often spreads deep into the layers of affected bowel tissue.

The Phase III DIVERSITY study is being conducted to assess the safety and efficacy of 100mg and 200mg filgotinib to be administered on a once-daily basis compared to placebo.

"With the FITZROY Phase II study, Galapagos demonstrated that filgotinib has a promising efficacy and safety profile in Crohn’s disease."

The study has enrolled 1,320 patients suffering from moderately to severely active Crohn’s disease, including those with prior biological therapy failure.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The start of the DIVERSITY study will also result to a $50m milestone payment from Gilead.

Galapagos chief scientific officer Dr Piet Wigerinck said: “With the FITZROY Phase II study, Galapagos demonstrated that filgotinib has a promising efficacy and safety profile in Crohn’s disease.

“The start of the Phase III DIVERSITY study is good news for patients with Crohn’s disease.”

Last year, Galapagos and Gilead entered into a global collaboration to develop and commercialise filgotinib in inflammatory indications, under which the companies began a Phase III trial in rheumatoid arthritis (RA) and Crohn’s disease.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU